APOE and Alzheimer disease: Analyses of the association between PSEN1 p.E318G and clinical AD status in an independent AD case-control series (n = 1,855, WU series) revealed that the risk of AD is significantly higher for p.E318G/APOE ε4 carriers (OR = 9.9 CI = 2.6–37.5, p = 1.7×10−4) compared to individuals carrying APOE ε4 alone (OR = 5.1, CI = 4.1–6.3, p = 3.2×10−59) (Table 5).